Summary of Key Points from the Conference Call Industry Overview - **Sector**: China's healthcare sector, specifically focusing on Biotech/Pharma and CRO/CDMO segments - **Trend**: Transitioning from "go-global beta" to "visibility-driven alpha" as the sector shows robust performance in 2025, driven by emerging assets expanding globally [1][2] Core Insights - **Investment Strategy Shift**: Investors are moving from beta trades based on licensing expectations to focusing on tangible execution and visibility into key data readouts and earnings delivery for 2026 [1][2] - **CRO/CDMO Outlook**: Positive outlook for CDMOs due to accelerated growth, strong product cycles, and reasonable valuations. Upgrades for WuXi AppTec and WuXi XDC to "Buy" [2][11] - **Biotech/Pharma Selectivity**: A more selective approach is advised, favoring companies with validated early data and realistic deal expectations. Preferred stocks include Kelun Biotech, Henlius, and Hansoh [2][7] - **MedTech Neutral Stance**: Cautious outlook on MedTech, with a recommendation to buy AngelAlign and Weigao, while maintaining a neutral stance overall [2][7] - **Healthcare Services Caution**: Downgraded outlook for healthcare services due to cost control measures and weak consumption cycles, with downgrades for Hygeia and Jinxin [2][7] Emerging Technologies - **AI and New Modalities**: Anticipated advancements in AI within healthcare and a strengthening of China's leadership in new modalities such as next-gen ADCs and innovative oligonucleotide medicines [3][7] - **Surgical Robotics**: 2026 is expected to be pivotal for surgical robotics commercialization, driven by new national billing rules [3] Financial Metrics and Projections - **Earnings Estimates**: EPS estimates for Chinese CDMOs/CROs revised up by 3%-4% for FY26-27 due to improved earnings visibility [11] - **Capex Normalization**: Capital expenditure is returning to growth levels, focusing on high-potential modalities and overseas expansion [10][21] - **Valuation Recovery**: Valuations for WuXi AppTec and WuXi XDC are expected to recover modestly as visibility improves, although they still trade at a discount compared to global peers [10][14] Market Dynamics - **Geopolitical Sensitivity**: Market sensitivity to geopolitical headlines has decreased, with a clearer distinction between sentiment risk and actual business impact [10][27] - **Outsourcing Trends**: Despite geopolitical uncertainties, outsourcing rates are expected to rise, driven by cost efficiency and access to specialized technologies [28] Key Risks and Considerations - **Biosecure Act Impact**: The Biosecure Act's implications are being closely monitored, with expectations that any structural reallocation of outsourcing away from China will be gradual [42] - **Client Behavior**: Client concerns regarding the Biosecure Act have diminished, with high retention rates noted for WuXi's services [13] Conclusion - The healthcare sector in China is poised for a significant transformation as it shifts towards visibility-driven investments. Key players in the CDMO and Biotech/Pharma segments are expected to benefit from improved earnings visibility and a supportive funding environment, while caution remains in MedTech and healthcare services due to ongoing economic pressures.

Summary of Key Takeaways from the JPM China Opportunity Forum Industry Overview - **Industry**: Healthcare - **Event**: JPM China Opportunity Forum held on January 21-22 Core Company Insights Hansoh Pharma - **Revenue Growth**: Innovative drugs are projected to drive total revenue growth, with their share expected to exceed 80% by FY25 [4] - **Product Pipeline**: Management aims to launch over 20 innovative medicines with more than 40 approved indications by 2030, indicating a sustainable growth trajectory [4] - **Key Product**: Almonertinib (AMEILE) is anticipated to contribute over 50% of innovative drug revenue by 2025, with peak sales estimates raised to RMB 8 billion by 2030 [4] - **Clinical Focus**: The 2026 strategy includes promoting newly approved adjuvant therapy and chemotherapy combinations for first-line non-small cell lung cancer (NSCLC), despite no inclusion in the National Reimbursement Drug List (NRDL) [4] Duality (Not Covered) - **Upcoming Events**: Key data updates expected from DB-1311 (B7H3) in late February, with additional readouts planned for 2026 [4] - **Financial Expectations**: Management anticipates milestone inflows of approximately USD 200 million in 2025-26 [4] - **Strategic Focus**: The company emphasizes a combo-first strategy and differentiated attributes of its antibody-drug conjugate (ADC) platform [4] Aier Eye - **Operational Normalization**: Management noted a gradual normalization in core operations, with average selling prices (ASP) stabilizing and selective demand recovery shaping the 2026 outlook [4] - **Cataract Market**: ASPs for cataracts decreased by approximately 7-8% year-over-year in the first nine months of 2025, with no immediate recovery expected [4] - **Self-Pay Growth**: Self-pay premium offerings, such as femtosecond cataract procedures, showed strong growth of over 20% year-over-year in 9M25 [5] Shenzhen New Industries (Not Covered) - **Growth Projections**: Management expects domestic revenue growth of 5-10% and overseas growth of 20-25% in 2026, driven by market share gains [5] - **ASP Erosion**: The guidance assumes only modest further ASP erosion, with expectations of a decline of less than 5% [5] - **Key Growth Drivers**: Continued share capture in tertiary-hospital replacements and integrated automation line deployments are highlighted as key growth drivers [5] Additional Insights - **Market Conditions**: The overall industry is facing pressure from domestic demand weakness tied to controlled medical insurance expense budgets, impacting test volumes [5] - **Overseas Operations**: Overseas markets, particularly in Europe, are expected to contribute positively to revenue growth, with a projected share of over 12% in FY25 [5] This summary encapsulates the critical insights and projections from the JPM China Opportunity Forum, focusing on the healthcare sector and specific companies within it.

Summary of the Conference Call on China Healthcare Sector Industry Overview - The conference call focused on the **China healthcare sector**, highlighting recent weaknesses and potential opportunities for 2026 [2][5][6]. Core Insights and Arguments - **Current Market Performance**: The Hang Seng Healthcare Index (HSHCI) has declined by **3.1%**, while the Hang Seng Index fell by **1.6%**. The HSHCI has dropped approximately **17%** from its year-to-date high in early October, with some small and mid-cap stocks down around **30%** [2][5]. - **Valuation Outlook**: Despite the current weakness, the fundamentals of the sector remain intact, and valuations are becoming more attractive, suggesting a potential rebound in 2026 [2][5][6]. - **Investment Recommendations**: - **Biotech**: Innovent and Kelun Biotech (rated Overweight) - **Pharma**: Hansoh Pharma and Hengrui-A (rated Overweight) - **CXO**: WuXi Apptec and WuXi XDC (rated Overweight) - Caution is advised regarding Akeso due to unclear updates on HARMONi-2 OS [2][5][6]. Upcoming Events and Legislative Considerations - **NRDL Price Negotiations**: Anticipated results from the National Reimbursement Drug List (NRDL) price negotiations are expected to be neutral to negative, reflecting the current weak sentiment [5][6]. - **Biosecure Act**: The potential passing of the Biosecure Act could be a negative headline event, although it is not expected to significantly impact China CXOs' business [5][6]. - **Medical Conferences**: Upcoming medical conferences in December (e.g., ASH'25 and SABCS'25) are not expected to affect overall sentiment towards the China healthcare sector [5][6]. Emerging Themes for 2026 - Potential interest in new drug modalities such as **siRNA** (small interfering RNA) and **RDC** (radionuclide drug conjugate) is anticipated, along with expectations for global Phase 3 data from out-licensed assets [5][6]. - A healthy out-licensing deal flow is expected in 2026, although it may not surpass the total deal size of 2025 due to several significant deals this year [6]. - The **JPM Global Healthcare Conference** in January 2026 is expected to provide further insights into the prospects for the China healthcare sector, with presentations from over a dozen public and private Chinese companies [6]. Key Companies Discussed - **Akeso** (9926.HK) - **Hansoh Pharma** (3692.HK) - **Hengrui** (600276.SS) - **Innovent Biologics** (1801.HK) - **Kelun Biotech** (6990.HK) - **WuXi AppTec** (603259.SS and 2359.HK) - **WuXi XDC** (2268.HK) [8]. Conclusion - The China healthcare sector is currently facing challenges but presents potential investment opportunities as valuations become more attractive. Key themes and developments in 2026 will be closely monitored, particularly in light of upcoming conferences and legislative changes [2][5][6].

Summary of Hansoh Pharma (3692.HK) Conference Call Company Overview - **Company**: Hansoh Pharma - **Ticker**: 3692.HK - **Market Cap**: HK$217.9 billion / $28.0 billion Key Industry Insights - **Sales Growth for Ameile**: - On-track sales progress for Ameile with a peak sales guidance of Rmb8 billion as a monotherapy, expected to be driven by adjuvant settings over the next two years [1][2] - Incremental sales contribution from adjuvant settings estimated at Rmb2-3 billion, with gradual sales ramp-up anticipated due to the need for expanded academic marketing and digestion of NRDL price cuts in 2026 [2] - **Overseas Development Progress**: - Smooth progress in overseas development for several assets: - GSK has started patient enrollment for global phase 3 clinical trials for HS-20093 (B7H3 ADC) targeting small cell lung cancer (SCLC) [3] - Merck plans to advance HS-10535 (oral GLP-1) to clinical stage by the end of 2025 [3] - Roche is exploring HS-20110 (CDH17 ADC) for colorectal cancer (CRC) [3] - The company aims to secure at least one out-licensing deal annually to generate sustainable collaboration income from upfront and milestone payments [3] - **Innovative Pipeline Deliveries**: - Targeting 8-10 new INDs (Investigational New Drug applications) each year to enhance the pipeline [4] - Focus on early-stage assets including: - HS-20122 (EGFR/cMet ADC) with patient dosing in 1H25 and phase 1 data readout expected in 2026 [4] - First siRNA program aimed at cardiovascular diseases, with IND filing by the end of 2025 [4] - Oral IL-23 currently in phase 1 [4] Financial Metrics and Valuation - **Price Target**: - Buy rating with a 12-month price target of HK$39.93, representing an upside of 8.4% from the current price of HK$36.82 [8][10] - **Revenue Forecasts**: - Projected revenues for the next few years: - 12/24: Rmb12,260.8 million - 12/25E: Rmb14,746.3 million - 12/26E: Rmb15,839.3 million - 12/27E: Rmb17,202.4 million [10] - **EBITDA Estimates**: - Expected EBITDA figures: - 12/24: Rmb4,315.8 million - 12/25E: Rmb5,027.2 million - 12/26E: Rmb4,959.9 million - 12/27E: Rmb5,197.5 million [10] Risks Identified - **Sales Risks**: - Potential for generics sales post VBP (Volume-Based Procurement) to fall below expectations [9] - **Ramp-Up Risks**: - Slower-than-expected ramp-up of novel drugs [9] - **R&D Risks**: - Risks associated with the innovative drug pipeline [9] - **Collaboration Income Risks**: - Below-expected collaboration income from global expansion of the pipeline [9] Conclusion Hansoh Pharma is positioned for growth with a strong pipeline and overseas development initiatives. However, potential risks related to sales performance, drug ramp-up, and R&D must be monitored closely. The company maintains a positive outlook with a solid financial forecast and strategic plans for innovation and market expansion.

Core Insights - The weight loss and diabetes drug market is experiencing significant growth, driven by demand for effective treatments and new competitors entering the space [1][3] - Eli Lilly and Novo Nordisk remain the leading companies, with Eli Lilly gaining market share and accounting for nearly 60% of prescriptions in the injectable obesity and diabetes class [2][9] - The market is projected to reach approximately $100 billion by the end of the decade, with a potential 25 to 50 million U.S. patients using GLP-1s by 2030 [3][12] Market Dynamics - Eli Lilly has outperformed Novo Nordisk, increasing its market share from 53% in Q1 to 57% in Q2 of the current year, attributed to superior efficacy and safety of its drugs [9][10] - Novo Nordisk is facing challenges, including a nearly 40% drop in stock value this year and a need to cut its workforce by 11.5% to regain market footing [11][14] - The competition is intensifying, with many pharmaceutical companies investing in obesity drugs, often through partnerships with smaller developers [4][42] Access and Coverage Issues - Access to GLP-1s remains limited due to insurance coverage gaps, with many insurers not covering obesity treatments, leading to high out-of-pocket costs for patients [5][23] - Coverage for GLP-1s for obesity has slightly increased, with 36% of surveyed companies providing such coverage, up from 34% in 2024 [24] - Employers are hesitant to cover these high-cost drugs due to concerns about long-term patient adherence and potential weight regain [25][28] Future Developments - Both Eli Lilly and Novo Nordisk are working on oral formulations of GLP-1s, which could significantly change market dynamics and improve patient access [30][34] - Analysts predict that oral pills could capture around 24% of the weight loss drug market by 2030, with Eli Lilly expected to lead this segment [34][35] - The success of new oral treatments will depend on their pricing and effectiveness compared to existing injectable options [40][39] Competitive Landscape - The market is seeing a variety of new entrants and experimental drugs, with companies exploring different mechanisms for weight loss and less frequent dosing [41][42] - Novo Nordisk and Eli Lilly are also looking into new hormone-targeting treatments to expand their portfolios beyond current offerings [45][46] - The competitive landscape is evolving, with potential partnerships between smaller biotech firms and larger pharmaceutical companies to enhance drug development [51]

Summary of Key Points from the Conference Call Industry Overview - **Industry**: Small-cap biotechnology in China - **Context**: The sector is at an inflection point after a four-year down cycle since 2021, with a structural upside for China's innovative drug pipeline in a global context [1][11][34] Core Insights and Arguments - **Survive-to-Thrive Roadmap**: Emphasis on efficient R&D, differentiated pipeline, and committed global partnerships as key growth drivers for small-cap biotech companies [1][11][12] - **US Small-Cap Biotech Learnings**: Historical performance shows a significant divergence between Thrivers (33X growth in market cap from 2005-2025) and Non-thrivers (66% shrinkage) [2][12][19] - **Differentiated Pipeline**: Companies focusing on rare diseases have shown better performance due to less costly and quicker drug development processes [2][12][30] - **Abbisko Therapeutics**: Initiated coverage with a Buy rating, targeting a 12-month DCF-based price of HK$27.10, indicating a 91% upside potential [4][60] Abbisko Therapeutics Highlights - **Pipeline**: Abbisko has a robust pipeline of 22 drug candidates, including 12 in clinical stages, with pimicotinib (CSF-1R inhibitor) expected to achieve US$1.6 billion in risk-adjusted peak sales [4][15][60] - **Global Partnership**: Strong endorsement from Merck KGaA enhances Abbisko's global visibility and market potential [4][15][60] - **R&D Expertise**: Abbisko's deep know-how in small-molecule R&D supports its strategic expansion roadmap into various therapeutic areas [4][15][60] Important but Overlooked Aspects - **Cash Runway Extension**: Companies are focusing on extending their cash runway, with more than half expected to have over five years of cash runway by 2025 [43][44] - **Strategic Pivots**: Companies are making aggressive strategic pivots, such as focusing on early-stage pipelines and leveraging partnerships to maximize asset value [47][48][51] - **Market Dynamics**: The funding environment for China healthcare is bottoming out, with a notable turnaround in private biotech funding expected [35][38] Conclusion - The small-cap biotech sector in China is transitioning from survival to growth, with companies like Abbisko positioned well for future success through strategic partnerships, efficient R&D, and a differentiated pipeline. The insights drawn from the US small-cap biotech experience provide valuable lessons for navigating this evolving landscape [1][11][12][60]

Summary of Hansoh Pharma Earnings Review Company Overview - **Company**: Hansoh Pharma (3692.HK) - **Industry**: Pharmaceuticals, specifically focusing on innovative drugs and collaborations Key Financial Highlights - **1H Sales**: Rmb7.4 billion, representing a **14.3% year-over-year increase** compared to the expected Rmb6.5 billion [1] - **Product Sales Growth**: Grew by **13.2% year-over-year**, driven by innovative drugs, particularly Ameile, which saw a **21% year-over-year increase** [1] - **Collaboration Income**: Exceeded expectations with Rmb853 million from Merck GLP-1 deal and Rmb804 million milestone payment from GSK [1] - **Earnings**: Rmb3.1 billion, up **15% year-over-year**, surpassing the expected Rmb2.1 billion [1] - **Core Earnings Growth**: Increased by **13% year-over-year**, slower than product sales due to a **20% year-over-year rise in R&D expenses** [1] Future Guidance - **Sales Guidance for 2025**: Management has raised the product sales growth forecast to **high-double-digit growth**, up from previous double-digit growth expectations [1] - **Ameile Sales Target**: Expected to achieve over Rmb8 billion by 2030, with a target of Rmb10 billion+ in 2025, driven by new indications and extended product life cycle strategies [2] Pipeline Developments - **Key Pipeline Assets**: - **HS-20093 (B7H3 ADC)**: Two phase 3 trials initiated in China for SCLC and osteosarcoma, with plans for pivotal stage advancement in 2025 [3] - **HS-20089 (B7H4 ADC)**: Pivotal study for ovarian cancer initiated in China, with global phase 3 trials expected by 2026 [3] - **HS-10535 (oral GLP-1)**: Global phase 1 studies to start by Merck in 2025 [3] - **HS-20094 (GLP-1/GIP)**: Moving to phase 3 stage by Regeneron in 2026 [3] Strategic Focus - **Collaboration Strategy**: Continues to be a key global expansion strategy, with efforts to self-run global phase 1 studies for selected oncology and immunology assets [8] - **Earnings Estimates Revision**: Earnings estimates for 2025, 2026, and 2027 have been revised up by **10.4%**, **8.9%**, and **6.3%** respectively, reflecting higher collaboration income and innovative drug sales [8] Valuation and Risks - **Price Target**: Increased to HK$39.93 from HK$34.83, based on a sum-of-the-parts (SOTP) valuation [9] - **Risks Identified**: - Generics sales may fall below expectations post VBP - Slower ramp-up of novel drugs - R&D risks in the innovative drug pipeline - Below-expected collaboration income from global expansion [10] Conclusion Hansoh Pharma shows strong financial performance in the first half of the year, with positive sales guidance and a robust pipeline of innovative drugs. The company's strategic focus on collaborations and self-running studies positions it well for future growth, despite identified risks in the generics market and R&D.

Investment Rating - The report assigns a "Buy" rating to Hansoh Pharma with a 12-month price target of HK$22.71, indicating a downside potential of 20.6% from the current price of HK$28.60 [8][9]. Core Insights - Management emphasizes encouraging progress in ex-China development for out-licensed assets, including B7H3 ADC, B7H4 ADC, and oral GLP-1, with a reiterated product sales guidance of double-digit growth in 2025 [1][2]. - The key product Ameile is projected to achieve peak sales of Rmb8 billion, with additional upside potential from combination therapies [1][3]. - The company anticipates deal-making opportunities from early-stage ADCs and next-generation disease modifiers for immunology diseases [1][7]. Summary by Sections Ex-China Development Progress - HS-20093 (B7H3 ADC) has received two breakthrough designations from the FDA for SCLC and osteosarcoma, with GSK planning pivotal studies by Q4 2025 [2]. - HS-20089 (B7H4 ADC) is set to commence pivotal trials in 2026 for gynecological cancers [2]. - HS-10535 (oral GLP-1) is expected to enter phase 1 trials in 2025, targeting multiple cardiovascular and metabolic diseases [2]. - HS-20094 (GLP-1/GIP) will focus on weight reduction strategies in combination with Regeneron's internal pipeline assets [2]. Sales Growth and Commercialization - Management guides for double-digit sales growth in 2025, driven by innovative drugs, particularly Ameile, which has a revised sales target of Rmb6 billion for 2025 [3][6]. - The potential for collaboration income is highlighted as a sustainable revenue driver, supported by a growing R&D pipeline with 8-10 new INDs each year [6]. Licensing and Deal-Making Opportunities - Potential licensing-out opportunities include early-stage pre-clinical assets and several ADCs that have entered clinical stages [7]. - Specific assets with deal-making potential include HS-20122 (EGFR/cMET ADC), HS-10370 (KRAS G12D), and others targeting immunology diseases [7].

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **biopharmaceutical sector in China**, highlighting its resurgence driven by innovation and increased deal activity with multinational corporations (MNCs) [1][2]. Core Insights - **Global Competitiveness**: China's pharma sector is confirmed to be globally competitive, with significant partnerships such as Summit Therapeutics' licensing agreement with Akeso for ivonescimab (up to $5 billion) and Pfizer's deal with 3SBio for SSGJ-707 (up to $6 billion) [2]. - **Investment in Obesity Treatments**: Companies are investing in the obesity treatment space, with notable deals including Merck's $1.9 billion agreement with Hansoh Pharma and Novo's $2 billion deal with United Bio-Technology [2]. - **Long-Term Winners**: AstraZeneca (AZN) and Sanofi (SAN) are identified as long-term winners in the region, with both companies actively investing and expanding their R&D presence in China [7][11]. R&D and Business Development Opportunities - **Rapid R&D Advancement**: China's biopharma industry is shifting from generics to genuine innovation, with improved R&D efficiency and lower costs [8][41]. - **Rich Pipeline of Assets**: MNCs are increasingly seeking business development (BD) deals in China, with a wealth of attractive pipeline assets available for international partnerships [9]. - **Key Asset Types**: Bispecific antibodies, GLP-1 therapies, and antibody-drug conjugates (ADCs) are highlighted as prominent areas for BD opportunities [10][65]. Market Dynamics - **Market Share Growth**: The share of innovative drugs in China's core hospital pharmaceutical market increased from 21% in 2015 to 29% in 2024, with local companies' share rising from 18.7% to 27.8% [24][25]. - **Declining Contribution**: There is a modest decline in China sales as a percentage of global sales among large-cap EU pharma companies, with AstraZeneca's share dropping from 20% in 2020 to an estimated 12% in 2024 [29][31]. Strategic Collaborations - **M&A Activity**: The report notes a boom in M&A activity as companies seek to acquire innovative pipeline assets amid global pricing pressures and patent expirations [40]. - **Emerging Global Innovation Hub**: China is becoming a global hub for innovative drug R&D, with a significant increase in out-licensing deals, reaching a total value of $50.8 billion in 2024 [40][48]. Specific Therapeutic Areas - **Bispecific Antibodies**: The report emphasizes the growing interest in bispecific antibodies, particularly those targeting PD-1/VEGF pathways, with significant licensing deals indicating global confidence in these assets [66][68]. - **GLP-1 Therapies**: The report outlines the evolution of GLP-1 therapies, with a focus on long-acting formulations and oral small molecules, highlighting numerous ongoing clinical trials and licensing deals [70][72]. - **Antibody-Drug Conjugates (ADCs)**: China is emerging as a leader in ADC innovation, with approximately 40% of the global ADC pipeline originating from China and a significant increase in international licensing transactions [77][78]. Conclusion - The biopharmaceutical sector in China is positioned for growth, with strong R&D capabilities, a rich pipeline of innovative assets, and increasing global interest from MNCs. Companies like AstraZeneca and Sanofi are well-positioned to capitalize on these opportunities, while the landscape for innovative therapies continues to evolve rapidly.